Geron also my be silent because of something happening with the FDA and must be close to some conclusion, and are in a very sensitive time about any leaked infor.
GRN1005 Phase 1 final results Nov. 14th. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
Something good is in the works. May buy some $3 calls.
Good luck in this rigged casino,
No comments:
Post a Comment